“In 2024 we built on our record of execution by advancing our highly differentiated portfolio of RAS-focused investigational drugs, making significant progress in building the organizational capabilities needed to drive the next stage of our strategy, and ending the year in an exceptionally strong financial position,” said Mark Goldsmith, chief executive officer and chairman of Revolution Medicines (RVMD). “In 2025 we aim to increase impact for patients with RAS-addicted tumors, including pancreatic cancer and lung cancer, by enrolling the ongoing registrational trials and opening additional pivotal trials in earlier lines of therapy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- RVMD Upcoming Earnings Report: What to Expect?
- Trump Trade: New administration to invest $20B to build data centers
- Revolution Medicines price target raised to $71 from $65 at UBS